Jacques Moisan
YOU?
Author Swipe
View article: Combination of a novel TCR Vβ chain-directed selective T cell activator with standard of care therapy for head and neck cancer improves antitumor responses and promotes regression of checkpoint-refractory tumor models
Combination of a novel TCR Vβ chain-directed selective T cell activator with standard of care therapy for head and neck cancer improves antitumor responses and promotes regression of checkpoint-refractory tumor models Open
Background Immune checkpoint blockade (ICB) treatment, alone or in combination with standard anticancer therapies, has led to important progress in the treatment of head and neck squamous cell carcinoma (HNSCC). Yet, a significant proporti…
View article: Data from Dual A<sub>2A</sub>/A<sub>2B</sub> Adenosine Receptor Antagonist M1069 Counteracts Immunosuppressive Mechanisms of Adenosine and Reduces Tumor Growth <i>In Vivo</i>
Data from Dual A<sub>2A</sub>/A<sub>2B</sub> Adenosine Receptor Antagonist M1069 Counteracts Immunosuppressive Mechanisms of Adenosine and Reduces Tumor Growth <i>In Vivo</i> Open
While A2A adenosine receptor (AR) was considered as a major contributor to adenosine-mediated immunosuppression, A2B, having the lowest affinity to adenosine, has also emerged as a potential contributor to tumor promotion. Therefore, in ad…
View article: Supp. Fig. 2 from Dual A<sub>2A</sub>/A<sub>2B</sub> Adenosine Receptor Antagonist M1069 Counteracts Immunosuppressive Mechanisms of Adenosine and Reduces Tumor Growth <i>In Vivo</i>
Supp. Fig. 2 from Dual A<sub>2A</sub>/A<sub>2B</sub> Adenosine Receptor Antagonist M1069 Counteracts Immunosuppressive Mechanisms of Adenosine and Reduces Tumor Growth <i>In Vivo</i> Open
Supplementary Figure 2
View article: Supplementary Methods from Dual A<sub>2A</sub>/A<sub>2B</sub> Adenosine Receptor Antagonist M1069 Counteracts Immunosuppressive Mechanisms of Adenosine and Reduces Tumor Growth <i>In Vivo</i>
Supplementary Methods from Dual A<sub>2A</sub>/A<sub>2B</sub> Adenosine Receptor Antagonist M1069 Counteracts Immunosuppressive Mechanisms of Adenosine and Reduces Tumor Growth <i>In Vivo</i> Open
Supplementary Materials and Methods
View article: Supp. Fig. 1 from Dual A<sub>2A</sub>/A<sub>2B</sub> Adenosine Receptor Antagonist M1069 Counteracts Immunosuppressive Mechanisms of Adenosine and Reduces Tumor Growth <i>In Vivo</i>
Supp. Fig. 1 from Dual A<sub>2A</sub>/A<sub>2B</sub> Adenosine Receptor Antagonist M1069 Counteracts Immunosuppressive Mechanisms of Adenosine and Reduces Tumor Growth <i>In Vivo</i> Open
Supplementary Figure 1
View article: Supp. Fig. 3 from Dual A<sub>2A</sub>/A<sub>2B</sub> Adenosine Receptor Antagonist M1069 Counteracts Immunosuppressive Mechanisms of Adenosine and Reduces Tumor Growth <i>In Vivo</i>
Supp. Fig. 3 from Dual A<sub>2A</sub>/A<sub>2B</sub> Adenosine Receptor Antagonist M1069 Counteracts Immunosuppressive Mechanisms of Adenosine and Reduces Tumor Growth <i>In Vivo</i> Open
Supplementary Figure 3
View article: Innate TCRβ-chain engagement drives human T cells toward distinct memory-like effector phenotypes with immunotherapeutic potentials
Innate TCRβ-chain engagement drives human T cells toward distinct memory-like effector phenotypes with immunotherapeutic potentials Open
Clonotypic αβ T cell responses to cargoes presented by major histocompatibility complex (MHC), MR1, or CD1 proteins underpin adaptive immunity. Those responses are mostly mediated by complementarity-determining region 3 motifs created by q…
View article: A T cell receptor β chain–directed antibody fusion molecule activates and expands subsets of T cells to promote antitumor activity
A T cell receptor β chain–directed antibody fusion molecule activates and expands subsets of T cells to promote antitumor activity Open
Despite the success of programmed cell death-1 (PD-1) and PD-1 ligand (PD-L1) inhibitors in treating solid tumors, only a proportion of patients respond. Here, we describe a first-in-class bifunctional therapeutic molecule, STAR0602, that …
View article: 804 Anti-tumor effect of a novel Vβ TCR-targeting bifunctional agent in combination with anti-PD1 in checkpoint refractory murine lung cancer models
804 Anti-tumor effect of a novel Vβ TCR-targeting bifunctional agent in combination with anti-PD1 in checkpoint refractory murine lung cancer models Open
Background Lung adenocarcinoma is the leading cause of cancer-related deaths nationally and worldwide. An unmet clinical need exists to overcome therapy resistance in metastatic lung cancer patients treated with the standard of care platin…
View article: Supplementary figures from <i>In Vitro</i> Priming of Adoptively Transferred T Cells with a RORγ Agonist Confers Durable Memory and Stemness <i>In Vivo</i>
Supplementary figures from <i>In Vitro</i> Priming of Adoptively Transferred T Cells with a RORγ Agonist Confers Durable Memory and Stemness <i>In Vivo</i> Open
Supplementary Figure S1 shows that RORgamma agonist treatment does not impact the transduction efficiency of CAR virus. Supplementary Figure S2 shows that RORgamma agonist treatment increases IL-17A secretion from TRP-1 Th0 and Th17 cells.…
View article: Data from <i>In Vitro</i> Priming of Adoptively Transferred T Cells with a RORγ Agonist Confers Durable Memory and Stemness <i>In Vivo</i>
Data from <i>In Vitro</i> Priming of Adoptively Transferred T Cells with a RORγ Agonist Confers Durable Memory and Stemness <i>In Vivo</i> Open
Adoptive T-cell transfer therapy is an FDA- approved treatment for leukemia that relies on the ex vivo expansion and reinfusion of a patient's immune cells, which can be engineered with a chimeric antigen receptor (CAR) for more efficient …
View article: Data from <i>In Vitro</i> Priming of Adoptively Transferred T Cells with a RORγ Agonist Confers Durable Memory and Stemness <i>In Vivo</i>
Data from <i>In Vitro</i> Priming of Adoptively Transferred T Cells with a RORγ Agonist Confers Durable Memory and Stemness <i>In Vivo</i> Open
Adoptive T-cell transfer therapy is an FDA- approved treatment for leukemia that relies on the ex vivo expansion and reinfusion of a patient's immune cells, which can be engineered with a chimeric antigen receptor (CAR) for more efficient …
View article: Supplementary figures from <i>In Vitro</i> Priming of Adoptively Transferred T Cells with a RORγ Agonist Confers Durable Memory and Stemness <i>In Vivo</i>
Supplementary figures from <i>In Vitro</i> Priming of Adoptively Transferred T Cells with a RORγ Agonist Confers Durable Memory and Stemness <i>In Vivo</i> Open
Supplementary Figure S1 shows that RORgamma agonist treatment does not impact the transduction efficiency of CAR virus. Supplementary Figure S2 shows that RORgamma agonist treatment increases IL-17A secretion from TRP-1 Th0 and Th17 cells.…
View article: Supplemental Figures from A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors
Supplemental Figures from A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors Open
Supplemental Figures
View article: Supplemental Figures from A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors
Supplemental Figures from A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors Open
Supplemental Figures
View article: Data from A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors
Data from A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors Open
Elevated levels of the proinflammatory cytokine IL6 are associated with poor survival outcomes in many cancers. Antibodies targeting IL6 and its receptor have been developed for chronic inflammatory disease, but they have not yet been show…
View article: Data from A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors
Data from A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors Open
Elevated levels of the proinflammatory cytokine IL6 are associated with poor survival outcomes in many cancers. Antibodies targeting IL6 and its receptor have been developed for chronic inflammatory disease, but they have not yet been show…
View article: 497 Evaluation of the TIGIT+ immune subset depletion effect of the anti-TIGIT antibody M6223
497 Evaluation of the TIGIT+ immune subset depletion effect of the anti-TIGIT antibody M6223 Open
Background T cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT) is an inhibitory receptor expressed on lymphocytes and has recently emerged as a target in cancer immunotherapy. M6223 …
View article: 1316 A novel class of T cell-activating antibody that selectively targets the TCR b chain to promote antitumor activity through activation and expansion of a novel, polyclonal effector memory T cell subset
1316 A novel class of T cell-activating antibody that selectively targets the TCR b chain to promote antitumor activity through activation and expansion of a novel, polyclonal effector memory T cell subset Open
Background Limitations with agents that enhance endogenous T cell responses to cancer, particularly in solid tumors, supports the study of alternative approaches. Directly targeting the variable (V) regions of the T cell receptor (TCR) is …
View article: 1337 Preclinical evaluation of STAR0602, a novel, first-in-class anti-TCR Vb targeted bispecific antibody with potent anti-tumor activity for PD-1 refractory solid tumors
1337 Preclinical evaluation of STAR0602, a novel, first-in-class anti-TCR Vb targeted bispecific antibody with potent anti-tumor activity for PD-1 refractory solid tumors Open
Background Despite recent advancements with immune checkpoint inhibitors (e.g., anti-PD1 inhibitors) many cancer patients develop treatment resistance, which supports the study of alternative approaches to induce potent and safe anti-tumor…
View article: 326 The anti-TIGIT antibody M6223 induces significant anti-tumor efficacy and immune response via multiple mechanisms of action
326 The anti-TIGIT antibody M6223 induces significant anti-tumor efficacy and immune response via multiple mechanisms of action Open
BackgroundM6223 is a fully human antagonistic anti-T cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT) antibody in IgG1 format with Fc-mediated effector function.MethodsThe ability of M6223 to block the interaction of TIGIT …
View article: 757 M9657, a novel tumor-targeted conditional anti-CD137 agonist displays MSLN-dependent anti-tumor immunity
757 M9657, a novel tumor-targeted conditional anti-CD137 agonist displays MSLN-dependent anti-tumor immunity Open
Background The costimulatory receptor CD137 (also known as 4-1BB and TNFRSF9) plays an important role in sustaining effective cytotoxic T cell immune responses and its agonism has been investigated as a cancer immunotherapy. In clinical tr…
View article: Discovery of LYC-55716: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor-γ (RORγ) Agonist for Use in Treating Cancer
Discovery of LYC-55716: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor-γ (RORγ) Agonist for Use in Treating Cancer Open
Retinoic acid receptor-related orphan receptor γ (RORc, RORγ, or NR1F3) is the nuclear receptor master transcription factor that drives the function and development of IL-17-producing T helper cells (Th17), cytotoxic T cells (Tc17), and su…
View article: Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors
Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors Open
Background M4112 is an oral, potent, and selective indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase 2 (TDO2) dual inhibitor. Here, we report preclinical data and first-in-human phase I data, including safety, tolerabilit…
View article: <i>In Vitro</i> Priming of Adoptively Transferred T Cells with a RORγ Agonist Confers Durable Memory and Stemness <i>In Vivo</i>
<i>In Vitro</i> Priming of Adoptively Transferred T Cells with a RORγ Agonist Confers Durable Memory and Stemness <i>In Vivo</i> Open
Adoptive T-cell transfer therapy is an FDA- approved treatment for leukemia that relies on the ex vivo expansion and reinfusion of a patient's immune cells, which can be engineered with a chimeric antigen receptor (CAR) for more efficient …
View article: A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn Binding
A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn Binding Open
Affinity- and stability-engineered variants of CTLA4-Ig fusion molecules with enhanced pharmacokinetic profiles could yield improved therapies with the potential of higher efficacy and greater convenience to patients. In this study, to our…
View article: Synthetic RORγ agonists regulate multiple pathways to enhance antitumor immunity
Synthetic RORγ agonists regulate multiple pathways to enhance antitumor immunity Open
RORγt is the key transcription factor controlling the development and function of CD4+ Th17 and CD8+ Tc17 cells. Across a range of human tumors, about 15% of the CD4+ T cell fraction in tumor-infiltrating lymphocytes are RORγ+ cells. To ev…